Education
About Us
Working with TipRanks
Follow Us
HealthCare Global Enterprises Ltd. (IN:HCG)
:HCG
HCG Stock Chart & Stats
₹655.45
-₹2.50(-0.51%)
At close: 4:00 PM EST
₹655.45
-₹2.50(-0.51%)
Day’s Range― - ―
52-Week Range₹489.27 - ₹799.36
Previous CloseN/A
Volume91.36K
Average Volume (3M)18.12K
Market Cap
₹80.99B
Enterprise Value₹93.89B
Total Cash (Recent Filing)₹2.02B
Total Debt (Recent Filing)₹17.68B
Price to Earnings (P/E)―
Beta0.50
Next Earnings
May 21, 2026EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding149,302,200
10 Day Avg. Volume16,611
30 Day Avg. Volume18,118
Financial Highlights & Ratios
PEG Ratio-21.26
Price to Book (P/B)7.99
Price to Sales (P/S)3.31
P/FCF Ratio68.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹728.00Price Target Upside11.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)3.27
Revenue Forecast (FY)₹25.50B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Margin ExpansionSustained top-line growth (17.35% year) alongside a 52.11% gross margin indicates durable demand and favorable service mix in oncology. This supports capacity utilization of high-value assets and provides a structural base for continued cash generation and reinvestment over the next 2-6 months.
Strong Operating Cash Flow & FCF GrowthRobust operating cash conversion (OCF/Net Income 7.14) and FCF growth of 9.39% show the business converts revenue to cash efficiently. That cash generation underpins capital spending for specialized oncology equipment and funds operations or deleveraging without relying solely on external financing.
Solid EBITDA MarginA ~19% EBITDA margin signals strong operating leverage for specialized cancer services and ability to absorb cost variations. Durable mid-teens+ margin at EBITDA level supports reinvestment in high-capex radiotherapy assets and helps sustain profitability as volumes scale over the medium term.
Bears Say
High LeverageA near-2x debt-to-equity ratio shows material reliance on debt financing. High leverage raises fixed interest burdens, reduces financial flexibility for expansion or capex, and increases refinancing risk if rates rise, constraining strategic options over the coming months.
Low Net Margin & Falling Net IncomeDespite revenue growth, a 2.0% net margin and declining net income point to cost, interest or non-operating pressures that compress final profitability. This limits retained earnings and resilience to shocks, making margin recovery and earnings stability key near-term risks for shareholders.
Earnings Volatility / EPS DeclineA ~67.5% drop in EPS signals material earnings volatility and potential one-off charges or operational dilution. Weak EPS trends can limit internal capital for growth, heighten dependence on external funding, and reduce investor confidence in sustained profitability over the medium term.
HealthCare Global Enterprises Ltd. News
HCG FAQ
What was HealthCare Global Enterprises Ltd.’s price range in the past 12 months?
HealthCare Global Enterprises Ltd. lowest stock price was ₹489.27 and its highest was ₹799.36 in the past 12 months.
What is HealthCare Global Enterprises Ltd.’s market cap?
HealthCare Global Enterprises Ltd.’s market cap is ₹80.99B.
When is HealthCare Global Enterprises Ltd.’s upcoming earnings report date?
HealthCare Global Enterprises Ltd.’s upcoming earnings report date is May 21, 2026 which is in 66 days.
How were HealthCare Global Enterprises Ltd.’s earnings last quarter?
HealthCare Global Enterprises Ltd. released its earnings results on Feb 05, 2026. The company reported ₹0.099 earnings per share for the quarter, missing the consensus estimate of ₹0.735 by -₹0.636.
Is HealthCare Global Enterprises Ltd. overvalued?
According to Wall Street analysts HealthCare Global Enterprises Ltd.’s price is currently Undervalued.
Does HealthCare Global Enterprises Ltd. pay dividends?
HealthCare Global Enterprises Ltd. does not currently pay dividends.
What is HealthCare Global Enterprises Ltd.’s EPS estimate?
HealthCare Global Enterprises Ltd.’s EPS estimate is 1.5.
How many shares outstanding does HealthCare Global Enterprises Ltd. have?
HealthCare Global Enterprises Ltd. has 149,302,200 shares outstanding.
What happened to HealthCare Global Enterprises Ltd.’s price movement after its last earnings report?
HealthCare Global Enterprises Ltd. reported an EPS of ₹0.099 in its last earnings report, missing expectations of ₹0.735. Following the earnings report the stock price went down -1.914%.
Which hedge fund is a major shareholder of HealthCare Global Enterprises Ltd.?
Currently, no hedge funds are holding shares in IN:HCG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HealthCare Global Enterprises Ltd.
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2021, it operated 23 cancer centers, including 1 center of excellence in Bengaluru, 2 freestanding diagnostic centers, and 1 day care chemotherapy center across India, as well as 1 cancer center in Africa. The company was founded in 1989 and is based in Bengaluru, India.
HCG Stock 12 Month Forecast
Average Price Target
₹728.00
▲(11.07% Upside)
Technical Analysis
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Global Health Limited
―
Narayana Hrudayalaya Ltd.
―